Are impulse control disorders the last Parkinson’s ‘taboo’?
PD in Practice
Author: Almaz OhenePublished: 27 July 2017
Prep: Cook: Serves:
The National Institute for Clinical Excellence (NICE) in the UK has just updated their guidelines on Parkinson’s disease, including additional material on impulse control disorders. Matt Eagles – who was diagnosed with young-onset Parkinson’s at just eight years old – opens up about how his wedding was almost cancelled due to his gambling impulses caused by dopamine agonist patches, how his neurologist and bank intervened, and how he hopes that these new guidelines will encourage others to speak out
In just a few weeks in the winter of 2013, Matt Eagles gambled away thousands of pounds that he and his fiancée had saved for their wedding, set for the following spring.
He wasn’t trying to sabotage his relationship; he was suffering from an impulse control disorder caused by his Parkinson’s medication. Some 18 months previously, he had started using a ‘dopamine agonist’ – a skin patch that slowly releases dopamine-like medication to stimulate the brain cells.
The patch had been working well and had allowed him to work as a sports photographer at the London 2012 Olympic Games. However, Matt believes that an emotional trauma, in which he and his partner suffered the loss of a baby girl, triggered a change in the way the medication worked for him.
He suddenly found himself engrossed in gambling apps on his phone.
Matt, who has lived with Parkinson’s for more than 40 years, recalls: “I’d go to the bathroom just to play on fruit machines, video poker and roulette in secret – losing the money that my fiancée and I had saved.”
But sometimes he would win the money back again.
“One day I was sitting with my fiancée in the lounge, secretly playing video poker. I won about seven thousands pounds in just one hand. I must have pumped my fist and shouted, “Get in!” or something, as my fiancée asked me what I was so pleased about.
“At that moment, I had to admit what I’d been doing and was so ashamed of myself. My fiancée said, ‘But this isn’t you Matt’. Since we’d both taken time to research the side effects of my Parkinson’s medications, we put two and two together and decided that I must be suffering from an impulse control disorder.
“I have a very good relationship with my specialist in London, and so when we called the clinic it took us just a week to get an appointment. I was still gambling during that week, but not nearly as much since everything was all out on the open.”
Matt Eagles shooting women’s rugby
The doctor decided to wean Matt from the medication and reduced the size of his patch over two to three weeks.
“As the days went by, I felt fewer impulses to gamble, which was such a relief.”
Although, by now, Matt had all but stopped gambling, he still had the issue of the lost wedding fund to contend with.
“My fiancée and I talked it out and many tears were shed. It was touch-and-go at times. Fortunately, she still wanted to get married but only on the proviso that I get the treatment that I needed, which, realistically, meant that I wouldn’t be able to go back on the dopamine agonists.
“The drugs really did help with mobility, so coming off them has meant that my Parkinson’s is worse. But it’s a consequence that I’ve learned to live with. The medication was literally ruining my life.”
In addition to helping control movement, balance and walking, dopamine also plays an important role in the part of the brain that controls reward and motivation.
Some Parkinson’s medications, particularly dopamine agonists – medications that act like dopamine to stimulate your brain cells – and, in some cases, levodopa – have been linked to impulsive and compulsive behaviour behavioural patterns.
Research has shown that around 17% of people with Parkinson’s who take dopamine agonists experience impulsive and compulsive behaviour, although it is not clear exactly how the medications cause the changes in behaviour.
Medications affect people in different ways, but research suggests that you may be more likely to experience impulsive and compulsive behaviour if you are:
– someone with a history of addictive behaviour
– someone who has a family history of gambling or alcohol abuse
– a younger person with Parkinson’s
– a single person who lives alone
Matt believes that people with Parkinson’s should be prepared to share their stories of impulse control disorders to help break the taboos surrounding them.
“I know so many people that have suffered severe consequences from dopamine agonists– people who haven’t told their specialists or families, but have admitted to having problems within in their private Parkinson’s communities.”
He also thinks that institutes such as banks need to be prepared to offer help.
“I was lucky in that my specialist was wrote a letter to my bank stating that it was the drugs that were making me reckless with my money, so the largest of my debts actually got written off.”
Matt and his wife have now been married for three years. He is not currently using dopamine agonist patches and no longer has gambling issues.
Matt Eagles telling a joke on his wedding day
You can read the new NICE guidelines on Parkinson’s disease in full here and the section on impulse control disorders here
The new campaign uncovering the hidden aspects of Parkinson’s disease
7 days ago
Is there a link between Parkinson’s disease and blood vessel dysfunction?
Scientists in Slovakia have investigated the link between blood vessel dysfunction and Parkinson’s – and found that dopamine agonists may have an impact. The team studied the function of the endothelium – a membrane which lines the heart and blood vessels and helps control blood fluidity – in 41 people with the condition and 41 people without. Endothelial function was then measured through a parameter that assessed how easily blood could flow through the vessels. The results showed that while more people with Parkinson’s had endothelial dysfunction compared to those without, the difference did not reach statistical significance. However, the researchers noted that the findings suggested “an association between smoking, dopamine agonists, and impaired endothelial function” in those with the condition. Outlining the study’s limitations, the team noted that more research is needed to explore this potential link.
New swab test may help with Parkinson’s disease diagnosis
Researchers at the University of Manchester, UK, have drawn on one woman’s sense of smell to develop a swab test that may be used to detect Parkinson’s. The scientists used the test to analyse sebum (a type of oily substance on the skin) in 79 people with Parkinson’s and a control group of 71 healthy individuals. The team identified more than 4,000 different compounds in the participant samples – including 500 that were unique to those living with the condition. The test was developed with the help of Joy Milne from Perth, Scotland, whose unique sense of smell meant that she noticed a change in her late husband Les’s odour twelve years before he was diagnosed with Parkinson’s. Speaking to the BBC, Professor Perdita Barran, who led the research, described the test as potentially “transformative” – and said that the team hopes to roll the test out to people in…
Could a national biobank help inform the future of Parkinson’s disease treatment in Australia?
A biobank is a collection of biological samples and data designed to be used for research. Now, researchers in Australia are working to build a biobank for Parkinson’s. As part of the project, the scientists are conducting scans of people that have been injected with fluorodopa – a substance that highlights dopamine in the brain. Participants include people living with Parkinson’s and a control group of people without the condition. The resulting database of scans will be used to create a national biobank that aims to inform treatment and research into the condition. Commenting on the study, Olivia Nasser – executive director at the Hospital Research Foundation, which is helping to fund the research – said, “Once we build up the biobank of scans, it can actually be used as an effective way to treat Parkinson’s.” The researchers encourage people with and without Parkinson’s to take part in the trial.